Profile data is unavailable for this security.
About the company
Cutia Therapeutics is a China-based company mainly engaged in the research and development and manufacture of dermatological biological drugs. The Company is committed to developing comprehensive solutions to meet the diverse needs of patients and consumers in a wide range of dermatological treatment and care markets. The Company is mainly engaged in clinical trials of its core product CU-20401. This product is mainly used to treat submental fat accumulation. The Company conducts its businesses in the domestic market and overseas markets.
- Revenue in HKD (TTM)213.64m
- Net income in HKD-563.32m
- Incorporated2019
- Employees360.00
- LocationCutia Therapeutics436 Heng Feng RoadJingan District, 20/F, Huanzhi BuildingSHANGHAI ChinaCHN
- Websitehttps://www.cutiatx.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Jbm (Healthcare) Ltd | 720.54m | 163.88m | 1.38bn | 279.00 | 8.59 | 1.38 | 6.32 | 1.92 | 0.1955 | 0.1955 | 0.8564 | 1.22 | 0.5069 | 4.64 | 4.38 | 2,582,581.00 | 12.10 | 4.38 | 15.12 | 5.52 | 51.75 | 46.47 | 23.86 | 12.69 | 1.27 | 54.59 | 0.0768 | 32.98 | 24.62 | 16.09 | 128.51 | 19.99 | 2.26 | -- |
| Essex Bio-Technology Ltd | 1.62bn | 262.89m | 1.59bn | 1.46k | 6.22 | 0.7885 | 5.00 | 0.9813 | 0.4499 | 0.4499 | 2.73 | 3.55 | 0.5587 | 2.62 | 2.73 | 1,093,064.00 | 9.07 | 11.20 | 12.10 | 14.73 | 89.78 | 86.01 | 16.24 | 19.77 | 1.61 | -- | 0.1397 | 16.16 | 29.51 | 7.72 | 22.11 | 3.56 | 7.29 | 7.39 |
| Ascletis Pharma Inc | 10.84m | -277.69m | 1.65bn | 219.00 | -- | 0.7307 | -- | 152.06 | -0.2675 | -0.2675 | 0.0104 | 2.31 | 0.0041 | 1.34 | 3.58 | 49,497.94 | -10.47 | -6.43 | -10.85 | -6.64 | -125.17 | 35.67 | -2,561.69 | -243.38 | 24.31 | -- | 0.004 | -- | 4.63 | -19.39 | 54.04 | -- | -20.44 | -- |
| Jacobson Pharma Corporation Ltd | 1.56bn | 253.22m | 1.66bn | 1.72k | 6.42 | 0.6778 | 4.20 | 1.06 | 0.1292 | 0.1292 | 0.7988 | 1.22 | 0.4116 | 2.84 | 7.32 | 907,070.30 | 6.67 | 4.30 | 8.55 | 5.57 | 42.92 | 41.25 | 16.20 | 13.73 | 1.46 | 9.53 | 0.2218 | 40.62 | 15.79 | -0.1401 | 1.31 | -3.05 | 24.06 | 4.10 |
| Cryofocus Medtech Shanghai Co Ltd | 44.60m | -114.15m | 1.67bn | 370.00 | -- | 13.20 | -- | 37.48 | -0.4774 | -0.4774 | 0.1865 | 0.5294 | 0.1881 | 0.418 | 4,369.58 | 113,767.20 | -51.79 | -- | -66.30 | -- | 76.35 | -- | -275.28 | -- | 2.06 | -80.68 | 0.2303 | -- | 50.83 | -- | 13.13 | -- | -- | -- |
| VIVA Biotech Holdings | 2.14bn | -341.64k | 1.75bn | 2.04k | -- | 0.4315 | 7.00 | 0.8173 | -0.0054 | -0.0054 | 1.04 | 1.90 | 0.2603 | 5.26 | 5.18 | 1,032,034.00 | 0.4017 | -1.39 | 0.5601 | -1.68 | 33.66 | 34.81 | 1.54 | -5.44 | 1.46 | 3.19 | 0.2884 | -- | -9.42 | 59.31 | 78.03 | -- | 31.98 | -- |
| Dawnrays Pharmaceutical (Holdings) Ltd | 1.16bn | 604.96m | 1.82bn | 1.18k | 3.00 | 0.5171 | 2.66 | 1.57 | 0.4027 | 0.4027 | 0.7715 | 2.34 | 0.2838 | 2.05 | 6.17 | 1,013,872.00 | 14.74 | 9.89 | 17.79 | 12.49 | 56.58 | 56.69 | 51.92 | 27.89 | 3.04 | -- | 0.0544 | 35.33 | -9.90 | 3.94 | -8.95 | 1.41 | 63.92 | 2.00 |
| Golden Throat Holdings Group Co Ltd | 1.08bn | 281.71m | 2.31bn | 860.00 | 8.19 | 1.67 | 7.13 | 2.13 | 0.381 | 0.381 | 1.46 | 1.86 | 0.4994 | 3.23 | 4.07 | 1,244,013.00 | 13.01 | 11.00 | 19.26 | 15.63 | 72.29 | 72.79 | 26.06 | 24.67 | 1.93 | 37.74 | 0.2814 | 83.15 | -3.09 | 6.73 | -11.04 | 19.61 | -32.13 | 38.94 |
| Cutia Therapeutics | 213.64m | -563.32m | 2.67bn | 360.00 | -- | 2.00 | -- | 12.48 | -1.85 | -1.85 | 0.7019 | 4.19 | 0.1206 | 2.31 | 6.93 | 716,902.80 | -31.81 | -- | -35.82 | -- | 50.33 | -- | -263.68 | -- | 4.82 | -- | 0.1818 | -- | 1,110.83 | -- | -253.30 | -- | -- | -- |
Data as of Nov 26 2024. Currency figures normalised to Cutia Therapeutics's reporting currency: Hong Kong Dollar HKD
8.69%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| FIL Investment Management (Hong Kong) Ltd.as of 28 May 2024 | 13.30m | 4.33% |
| Harvest Global Investments Ltd.as of 09 Jun 2023 | 7.16m | 2.33% |
| FIL Investment Management (Singapore) Ltd.as of 28 May 2024 | 4.14m | 1.35% |
| FIL Investments Internationalas of 30 Sep 2024 | 1.81m | 0.59% |
| Bosera Asset Management Co., Ltd.as of 30 Jun 2024 | 205.60k | 0.07% |
| Huashang Fund Management Co., Ltd.as of 30 Jun 2024 | 67.40k | 0.02% |
| Harvest Fund Management Co., Ltd.as of 30 Jun 2024 | 5.40k | 0.00% |
| E Fund Management Co., Ltd.as of 30 Jun 2024 | 4.14k | 0.00% |
| FIL Investment Advisors (UK) Ltd.as of 31 Oct 2023 | 1.00 | 0.00% |
More ▼
Data from 30 Jun 2024 - 21 Nov 2024Source: FactSet Research Systems Inc.
